The nanocomplex materials to be provided by PeptiMed will harbor motifs that bind to cell adhesion molecules on the surface of cancer cells and deliver an siRNA payload that silences the oncogene, EVI1. Initially, the NCL will assess the physical and chemical properties of the nanocomplexes followed by their purity and sterility in cell culture models. A second phase of testing for various modes of toxicity may be performed in animal models.
"We are profoundly pleased to work with the NCL to further our understanding of PeptiMed nanomaterials," stated
PeptiMed co-founder Dr.
Most Popular Stories
- Criminal Investigation Opened Into James Foley's Death
- Apple Stock Bounces Back Big Time
- Is Diversity in the Eye of the Beholder?
- Investors Betting on ECB Stimulus Measures
- 'Mythbusters' Build Team Gets the Boot
- Jennifer Lopez Would Marry Again
- Hackers Get Homeland Security Employee Records
- Florida Judge Rules in Favor of GOP Voter Map
- Mo'Ne Davis a Big Winner Despite Loss
- Advocacy Group Calls for Chrysler Probe